angiotensin-(1-7) / Erasme Hospital - LARVOL DELTA

Alterations in the renin-angiotensin system during septic shock. (PubMed, Ann Intensive Care) - "Septic shock was associated with increased Ang I/Ang II and Ang-(1-7)/Ang II ratios, along with reduced cACE activity, increased cACE2 activity, and elevated cDPP3 concentrations compared to healthy controls."

Journal • Chronic Kidney Disease • Hepatology • Infectious Disease • Liver Failure • Nephrology • Renal Disease • Septic Shock

Alterations in the Renin-Angiotensin System in Experimental Septic Shock. (PubMed, Crit Care Explor) - "The study highlighted dynamic shifts in the RAS during septic shock, characterized by reduced circulating ACE activity, elevated angiotensin I/II ratio, and a shift toward the angiotensin-(1-7) axis. These findings suggest an adaptive response within the RAS, potentially offering new insights into sepsis management and therapeutic targets."

Journal • Critical care • Infectious Disease • Septic Shock

Angiotensin-(1-7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1-2 randomized clinical trial. (PubMed, Ann Intensive Care) - P1/2 | "The main findings of our study indicate that continuous intravenous infusion of Angiotensin-(1-7) at 10 mcg/Kg day in COVID-19 patients admitted to the ICU with severe pneumonia is safe. In Phase II intention to treat analysis, there was no significant difference in OFD between groups. Trial Registration ClinicalTrials.gov Identifier: NCT04633772-Registro Brasileiro de Ensaios Clínicos, UTN number: U1111-1255-7167."

Clinical • Journal • P1/2 data • Cardiovascular • Critical care • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Angiotensin 1-7 in an experimental septic shock model. (PubMed, Crit Care) - "In this experimental septic shock model, early Ang-(1-7) infusion prevented the development of septic shock, reduced norepinephrine requirements, limited interleukine-6 increase and prevented renal dysfunction."

Journal • Anesthesia • Infectious Disease • Inflammation • Nephrology • Renal Disease • Septic Shock • IL6

Angiotensin-(1-7) as a Potential Therapeutic Strategy for Delayed Cerebral Ischemia in Subarachnoid Hemorrhage. (PubMed, Front Immunol) - "In the presence of SAH, Ang-(1-7)/MasR neuroprotective and modulating properties could help reduce brain damage by acting on neuroinflammation, and through direct vascular and anti-thrombotic effects. Here we review the role of RAS in brain ischemia, with specific focus on SAH and the therapeutic potential of Ang-(1-7)."

Journal • Review • Cardiovascular • CNS Disorders • Cognitive Disorders • Depression • Developmental Disorders • Fibrosis • Hematological Disorders • Immunology • Inflammation • Ischemic stroke • Movement Disorders • Parkinson's Disease • Psychiatry • Subarachnoid Hemorrhage • Vascular Neurology

Use of Angiotensin-(1-7) in COVID-19 (clinicaltrials.gov) - P1/2; N=112; Completed; Sponsor: Erasme University Hospital; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IL6

Use of Angiotensin-(1-7) in COVID-19 (clinicaltrials.gov) - P1/2; N=130; Recruiting; Sponsor: Erasme University Hospital; Trial completion date: Feb 2021 ➔ Dec 2021; Trial primary completion date: Feb 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IL6

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (clinicaltrials.gov) - P2/3; N=60; Not yet recruiting; Sponsor: Erasme University Hospital; Trial completion date: Jun 2021 ➔ Jun 2023; Trial primary completion date: Dec 2020 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG • IL10 • IL2 • IL6 • TNFA

Use of Angiotensin-(1-7) in COVID-19 (clinicaltrials.gov) - P1/2; N=130; Recruiting; Sponsor: Erasme University Hospital

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial (clinicaltrials.gov) - P2/3; N=60; Not yet recruiting; Sponsor: Erasme University Hospital; Trial completion date: Jun 2020 ➔ Jun 2021; Initiation date: Mar 2020 ➔ Sep 2020; Trial primary completion date: May 2020 ➔ Dec 2020

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases